On Monday, IsoRay, Inc. (NYSEMKT:ISR)’s shares declined -9.89% to $1.64.
IsoRay, Inc. (ISR) declared that a number of industry leaders talk about the successes achieved by their patients in a variety of body sites being treated with IsoRay’s Cesium-131 internal radiation (brachytherapy) cancer seeds at the “Advances in Brachytherapy” symposium, held at Weill Cornell on Friday and Saturday.
soRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States.
Comstock Resources Inc (NYSE:CRK)’s shares dropped -8.84% to $4.23.
Comstock Resources Inc (CRK) stated financial and operating results for the three months ended March 31, 2015.
Comstock stated a net loss of $78.5 million or $1.71 per share for the first quarter of 2015 as contrast to net income of $1.2 million or 2¢ per diluted share for the first quarter of 2014. The first quarter 2015 results comprise impairments on unevaluated acreage and oil and gas properties of $40.8 million ($26.5 million after tax or 58¢ per share), drilling rig termination fees of $1.8 million ($1.2 million after tax or 3¢ per share) and a net loss on extinguishment of debt of $2.7 million ($1.8 million after tax or 4¢ per share). Financial results for the first quarter of 2014 comprised of an unrealized loss from derivative financial instruments of $3.6 million ($2.4 million after tax or 6¢ per share). Not taking into account these items from each year`s results, the net loss for the first quarter of 2015 would have been $49.0 million or $1.06 per share as contrast to net income of $3.6 million or 8¢ per diluted share in the first quarter of 2014.
In the first quarter of 2015, the Company accomplished four horizontal Eagle Ford shale wells (2.2 net) in South Texas. These wells had an average per well initial production rate of 747 barrels of oil equivalent (“BOE”) per day (90% oil). The Company has also accomplished four wells (3.8 net) on its Burleson County, Texas acreage. Three of these wells (the Henry A2, A3 and A4) had an average per well initial production rate of 764 BOE per day (80% oil). The Lewis A1 H had an initial rate of 101 barrels of oil and 2.9 million cubic feet of gas. The Company has an additional four wells (4.0 net) in Burleson County, Texas that are cleaning up after their respective fracture treatments.
Comstock Resources, Inc., an independent energy company, acquires, develops, explores, and produces oil and natural gas properties in the United States.
At the end of Monday’s trade, Etsy Inc (NASDAQ:ETSY)‘s shares dipped -8.19% to $20.85.
Etsy Inc (ETSY) declared that it will release its financial results for the first quarter of 2015 on Tuesday, May 19, 2015 in a press release after the market closes. Etsy will host a conference call to talk about those results at 5:30 p.m. Eastern Time on the same day.
Etsy, Inc. operates online and offline marketplaces to buy and sell handmade items, vintage goods, and craft supplies. Its platform connects sellers and buyers to sell or buy products for art, home and living, mobile accessories, jewelry, wedding, and others.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), ended its Monday’s trading session with -7.56% loss, and closed at $0.470.
AEterna Zentaris Inc. (USA) (AEZS) stated financial and operating results for the first quarter ended March 31, 2015.
Research and development (“R&D”) costs, were $4.5 million for the three-month period ended March 31, 2015, contrast to $5.8 million for the same period in 2014. This decrease is attributable to lower comparative employee compensation and benefits costs, facilities rent and maintenance in addition to other costs. A substantial portion of this decrease is due to the realization of cost savings in connection with the Company’s global resource optimization program in addition to the lower comparative exchange rate of the EUR against the US dollar. This decrease was partly compensated by higher third-party costs, mostly related to the Company’s ZoptEC Phase 3 clinical trial in endometrial cancer.
Net loss for the three-month period ended March 31, 2015 was $9.7 million, or $0.13 per basic and diluted share, contrast to $4.4 million, or $0.08 per basic and diluted share, for the same period in 2014. This enhance in net loss is due largely to higher comparative SG&A expenses and to higher comparative net finance costs, partially offset by lower comparative R&D costs.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
